Evaluation of Recent Trends in Treatment Patterns Among Men With Benign Prostatic Hyperplasia
|
|
- Basil Bishop
- 6 years ago
- Views:
Transcription
1 469245JMHXXX / A merican Journal of Men s HealthKruep et al. Article Evaluation of Recent Trends in Treatment Patterns Among Men With Benign Prostatic Hyperplasia American Journal of Men s Health 7(3) The Author(s) 2012 Reprints and permissions: sagepub.com/journalspermissions.nav DOI: / jmh.sagepub.com Eric J. Kruep, PharmD, MS 1, Bridgett B. Goodwin, PhD 2, and Sham Chaudhari, PharmB, MS 1 Abstract Although there is an abundance of evidence regarding clinical efficacy and safety of benign prostatic hyperplasia (BPH) treatment, real-world evidence is lacking for pharmacotherapy utilization and trends. It is unclear how evidence demonstrating the efficacy of combination 5-alpha reductase inhibitors and alpha blockers for improving symptoms and reducing risk of disease progression translates into real-world practice for the treatment of BPH. A retrospective study of a database was conducted to describe pharmacotherapy utilization/trends in the treatment of BPH among patients in the managed care setting. After inclusion and exclusion criteria were applied, the final sample size was 107,038. The proportion of patients with BPH receiving 5-alpha reductase inhibitors therapy increased (21.1% in 2003 to 30.5% in 2007), as did the proportion receiving combination therapy (10.7% and 16.1%, respectively). We observed an almost 50% increase in 5-alpha reductase inhibitors use over 5 years and a 60% increase in the use of combination 5-alpha reductase inhibitors/alpha blockers therapy. Keywords benign prostatic hyperplasia, urologic disorders, combination treatment, disease progression, lower urinary tract symptoms Introduction Benign prostatic hyperplasia (BPH) is a chronic progressive urologic disorder commonly associated with bothersome lower urinary tract symptoms (LUTS). The prevalence of BPH and resultant economic burden is high, ranking as the fourth-most-commonly diagnosed disorder in men older than 50 years, with an estimated $1.1 billion in total direct medical costs each year (Issa, Fenter, Black, Grogg, & Kruep, 2006; Fenter, Naslund, Shah, Eaddy, & Black, 2006; Wei, Calhoun, & Jacobsen, 2005). Approximately, one in four men will require medical care for BPH by the age of 80 years, and more than 90% will have histological evidence of BPH by the age of 85 years (American Urological Association, 2010; McConnell, Barry, & Bruskewitz, 1994; Roehrborn et al., 2003). As BPH progresses, men may develop acute urinary retention (AUR) and other serious complications that may require surgical intervention (Emberton et al., 2003). Beyond the direct clinical manifestations and economic burden, BPH is associated with diminished quality of life, with increasing severity of symptoms associated with lower general health perception, physical condition, and role limitations, as well as impaired sexual functioning (Roberts et al., 1997; Rosen et al., 2003). Historically, therapy for BPH has focused on surgical intervention and symptom management. However, over the past several years, there has been a shift toward pharmacotherapy for first-line treatment of LUTS (Sarma et al., 2005). The complex nature of BPH involves the prostate, bladder, and central nervous system, thus, allowing for several therapeutic targets (Desgrandchamps, 2004). Current medical treatment guidelines recommend combination therapy incorporating alpha blockers (ABs) and 5-alpha reductase inhibitors (5ARIs) for patients experiencing LUTS associated with demonstrable prostatic enlargement (American Urological Association, 2010; Desgrandchamps, 2004). Although AB therapy provides rapid relief of symptoms (within 1 week of initial administration) by decreasing 1 Xcenda, Palm Harbor, FL, USA 2 GlaxoSmithKline, Research Triangle Park, NC, USA Corresponding Author: Eric J. Kruep, Xcenda, 4114 Woodlands Parkway, Suite 500, Palm Harbor, FL 34685, USA. eric.kruep@xcenda.com
2 Kruep et al. 215 smooth muscle tone in the prostate, urethra, and bladder (Dunn, Matheson, & Faulds, 2002), ABs have no effect on prostate volume and therefore do not affect the risk of disease progression. Conversely, although symptom improvement takes longer (3-6 months) for 5ARI therapy, it also decreases risk of disease progression by inhibiting the conversion of testosterone to dihydrotestosterone, a hormone that stimulates prostate growth (American Urological Association, 2010; Rigatti et al., 2003). 5ARI therapy has demonstrated a 57% reduced relative risk of AUR and a 48% reduced relative risk of surgical intervention compared with placebo at 2 years (both p <.001 vs. placebo; Roehrborn, Boyle, Nickel, Hoefner, & Andriole, 2002), and these reductions were maintained to 4 years during open-label phases of the studies (Debruyne et al., 2004). Therefore, combination 5ARI + AB therapy not only provides short- and long-term relief of symptoms but also decreases the risk of disease progression and associated surgical intervention and complications. A growing body of evidence supports the use of combination 5ARI + AB therapy. The European PREDICT trial (Kirby et al., 2003) reported that patients receiving combination doxazosin + finasteride had significant improvement in American Urological Association symptom scores (p <.01 vs. finasteride alone) and peak flow rate (p <.01 vs. finasteride alone) compared with patients receiving finasteride monotherapy or placebo. The European Medical Therapy of Prostatic Symptoms study (McConnell et al., 2003) reported that combination 5ARI + AB was associated with significantly lower risk of clinical progression (risk reduction of 66% for the comparison with placebo, p <.001; p <.001 for each pairwise comparison of combination therapy with monotherapy) and improved symptom scores compared with either agent alone (p <.001 for the 5ARI + AB combination therapy group vs. the 5ARI monotherapy group; p =.006 for the 5ARI + AB combination therapy group vs. the AB monotherapy group). Risk of urinary retention and the need for invasive therapy was reported to be reduced in patients receiving either combination 5ARI + AB therapy (p <.001) or 5ARI monotherapy (p <.001) but not in patients receiving AB monotherapy. More recently, the CombAT study (Roehrborn et al., 2009; Roehrborn et al., 2010) reported similar results. Spanning 4 years, this study demonstrated that combination therapy was associated with reduced risk of clinical progression (p <.001 for both comparisons) and greater improvement in symptoms (p <.01 for both comparisons) compared with either AB or 5ARI monotherapy, as well as reduced risk of AUR or BPH-related surgery compared with AB monotherapy (reduction in relative risk of 65.8%; Roehrborn et al., 2010). Results from observational studies have paralleled the conclusions of the pivotal clinical trials. Naslund and colleagues identified that 5ARI therapy was associated with lower rates of AUR compared with patients receiving AB monotherapy (Naslund, Issa, Grogg, Eaddy, & Black, 2006), and more recently demonstrated that delayed initiation of 5ARI therapy among patients receiving combination 5ARI + AB therapy was associated with increased risk of clinical progression (Naslund, Eaddy, Hogue, Kruep, & Shah, 2009). Given the accumulating evidence from clinical trials demonstrating the benefit of combination 5ARI + AB therapy in terms of symptom improvement and disease progression, one would expect that this therapeutic combination would be used to an increasing degree. Although there is an abundance of evidence regarding clinical efficacy and safety of BPH treatment, real-world evidence is lacking for pharmacotherapy utilization and trends. To the authors knowledge, there have not been any retrospective database analyses to characterize the real-world use of these medications published to date. As such, the purpose of this study was to describe pharmacotherapy utilization and trends in the treatment of BPH among patients in the managed-care setting over a 4-year period of time. Materials and Methods This was a retrospective cohort study using data on BPH patients from the MarketScan Database. This database contains commercial and Medicare medical and pharmacy claims data that is sourced directly from health plans and employers, representing approximately 18 to 20 million individuals annually from multiple states. The time period for this study spanned 5½ years, from January 1, 2003 to June 30, Men aged 50 years and older who were treated with an AB or 5ARI alone or in combination between July 1, 2003 and June 30, 2007 were eligible for study inclusion. This enrollment period allowed for treatment patterns to be evaluated 12 months after the index date, defined as the first fill for a BPHrelated prescription. A 6-month period preceding the index date allowed for an evaluation of baseline characteristics of patients. Documentation of a BPH diagnosis among patients was evaluated in the 6-month preperiod and 1-year postindex assessment period. The study design employed for identifying eligible patients and for evaluating treatment patterns is illustrated in Figure 1. Exclusion criteria were patients who had prostate cancer (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9] codes 185, , 233.4, 236.5, 239.5, V10.46) or bladder cancer (ICD-9 codes 188, 198.1, 223.3, 233.7, 239.4, V10.51) during the study period; had prostate-related surgery (Current Procedural Terminology [CPT] codes 52601, 52612, 52614, 52620, 52640, 52647, 52648, 55801, 55821, 55831, 52850, 52852, 52852, 52853) prior to or within 1 month of the index date; received finasteride dose indicative of male
3 216 American Journal of Men s Health 7(3) Study period Enrollment period 01/01/2003 6/30/ /01/2003 6/30/2007 History period Index treatment Follow-up period (6 months) date (12 months) Figure 1. Study design. Patients with AB or 5ARI therapy in the enrollment period N=585,932 Exclusion Criteria Patients Excluded Younger than 50 years 73,209 No continuous enrollment from 6 months prior through 12 months after the index date 258,553 Prostate or bladder cancer 3,218 Used finasteride 1 mg for baldness 634 Prostate surgery within 1 month of index date 1,925 No documented BPH diagnosis 141,355 Patients with AB or 5ARI included in the study N=107,038 Figure 2. Patient selection algorithm. Note. 5ARI = 5-alpha reductase inhibitor; AB = alpha blocker; BPH = benign prostatic hyperplasia. pattern baldness; were not continuously eligible for 6 months pre- and 12 months postinitial prescription; or did not have a documented BPH diagnosis. Patients were assigned to treatment groups based on the presence and timing of fills for classes of BPH-related medications. The following five groups were defined: 1. AB monotherapy; 2. 5ARI monotherapy; 3. Early combination, AB + 5ARI combination therapy (within 30 days); 4. Delayed combination, AB + 5ARI combination therapy (with 5ARI starting more than 30 days after AB but within 1 year); 5. 5ARI before AB. Changes in these treatment groups were evaluated across the years of data. Accordingly, all analyses were descriptive in nature and were conducted using SAS version 9.2. Results The application of study exclusion criteria and resultant attrition of the potential pool of study patients are illustrated in Figure 2. A total of 585,932 patients were initially identified, who were treated with AB and/or 5ARI therapy during the study enrollment period. Reasons for exclusion and resultant patient attrition are illustrated in Figure 2. After applying all inclusion and exclusion criteria, a total of 107,038 evaluable patients (18% of initially identified patients) remained for analysis.
4 Kruep et al. 217 Table 1. Numbers of Patients by Treatment Group. Medication(s) of interest Patients, n (%) AB monotherapy 78,324 (73.2) 5ARI monotherapy 9225 (8.6) Early 5ARI 30 days 7001 (6.5) Delayed 5ARI >30 days and 1 year 8378 (7.8) 5ARI before AB 4110 (3.8) Note. 5ARI = 5-alpha reductase inhibitor; AB = alpha blocker. Figure 3. Treatment patterns over time. Note. 5ARI = 5-alpha reductase inhibitor; AB = alpha blocker; BPH = benign prostatic hyperplasia. The distribution of patients across treatment groups are presented in Table 1. The majority of patients (n = 78,324; 73.2%) received AB monotherapy during the study time period, whereas 8.6% (n = 9,225) received 5ARI monotherapy. A total of 15,379 patients (14.3%) received combination 5ARI + AB therapy: 6.5% of patients (n = 7,001) received early 5ARI therapy (within 30 days of AB therapy), whereas 7.8% of patients (n = 8,378) received delayed 5ARI therapy. Finally, 3.8% (n = 4,110) received 5ARI therapy followed by AB therapy. Trends in treatment patterns over time among patients treated for BPH are depicted in Figure 3. The proportion of patients with AB monotherapy decreased from 78.9% in 2003 to 69.5% in Or, conversely, the proportion of BPH patients receiving 5ARI therapy increased from 21.1% in 2003 to 30.5% in The proportion of patients receiving combination therapy (early and delayed 5ARI therapy) over the years was as follows: 10.7% in 2003, 11.7% in 2004, 15.2% in 2005, 16.5% in 2006, and 16.1% in Discussion Despite the demonstrated clinical efficacy of 5ARI therapy, results of this retrospective study suggest that a large proportion (73%) of BPH patents continue to receive only AB therapy. Furthermore, combination 5ARI + AB therapy was used in only 14% of patients treated from 2003 to However, there was a noted 50% increase in 5ARI use over the study period and a 60% increase in combination use. Prior to the time frame of this study, pharmacotherapy for BPH focused primarily on symptom management. However, results from several pivotal trials, including the Medical Therapy of Prostatic Symptoms study (McConnell et al., 2003), and the PREDICT trial (Kirby et al., 2003) released in 2003 highlighted the potential benefit of a more comprehensive strategy of combined symptom management and disease modification. The complementary mechanisms of action of AB therapy, which provides rapid symptom improvement, and 5ARI therapy, which improves symptoms, reduces prostate size, and reduces the risk of disease progression over time, make them a valuable and potentially superior alternative to monotherapy. With the accumulation of evidence and increased awareness of the clinical benefit of combination 5ARI + AB therapy, one might expect a resultant change in treatment patterns from an emphasis on symptom management (i.e., AB monotherapy) to combination therapy. In our current study, we did observe moderate shifts in real-world treatment patterns over the time frame of the study. Although AB monotherapy remained the predominant choice of therapy, utilization of 5ARI therapy overall (alone or in combination) increased from approximately 20% to 30% from 2003 to There was an observed trend in increasing utilization of combination 5ARI + AB therapy as well. Over the 5-year time frame of the study, we saw that utilization of combination therapy increased by approximately 50%, from 10.7% in 2003 to 16.1% in More recent research suggests that early initiation of 5ARI therapy in combination with AB therapy may be associated with lower risk of disease progression compared with patients with delayed initiation of 5ARI therapy (Naslund et al., 2009). In this current study, we found that among patients receiving combination therapy (N = 15,387), 45.5% of those (n = 7,001) were early initiators of 5ARI therapy. This proportion did not change significantly over time: 45.6% of patients receiving combination therapy in 2003 were early 5ARI initiators versus 44.9% among combination therapy patients in Although this study highlights changes in treatment trends over recent years, there are inherent limitations that should be mentioned. Because of the deficiency of clinical data available in this claim-based analysis, diagnosis of BPH was dependent on a diagnostic code and lacked the clinical context that would be provided with clinical data (e.g., prostate size, American Urological Association symptom score, etc.). Given the nature of claims data, a substantial number of patients
5 218 American Journal of Men s Health 7(3) were excluded because of an insufficient enrollment period, which may affect the generalizability of results. Furthermore, a large number of patients receiving BPHrelated therapy did not have a documented diagnosis of BPH and were not included in the current assessment of therapy utilization. Although this may introduce constraints on how these data are interpreted, it also highlights an important point that the true burden of BPH may be underestimated because of incomplete documentation of this disease. Finally, although the data used for this study included multiple payer types (commercial and Medicare) and should be considered a strength, our results may not reflect treatment patterns among indigent and underserved populations. In conclusion, this study sheds light on the recent treatment patterns of patients with BPH receiving pharmacotherapy in a managed care setting. Although there has been a slight shift in therapy utilization from AB monotherapy to combination 5ARI + AB therapy over time, the latest data suggest that there remains a large proportion of the patient population who may be receiving suboptimal therapy. Future studies should attempt to further characterize this subgroup in an effort to identify high-risk patients who might benefit from combination therapy. Declaration of Conflicting Interests The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: BBG is an employee of GlaxoSmithKline. EJK and SC are employees of Xcenda, a consulting company that received payment from GlaxoSmithKline to assist with this study. Funding The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by GlaxoSmithKline. References American Urological Association. (2010). AUA practice guidelines committee. Guideline on the management of benign prostatic hyperplasia. Retrieved from org/content/guidelines-and-quality-care/clinical-guidelines. cfm?sub=bph Debruyne, F., Barkin, J., van Erps, P., Reis, M., Tammela, T. L., & Roehrborn, C. (2004). Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. European Urology, 46, Desgrandchamps, F. (2004). Who will benefit from combination therapy? The role of 5 alpha reductase inhibitors and alpha blockade: A reflection from MTOPS. Current Opinion in Urology, 14, Dunn, C. J., Matheson, A., & Faulds, D. M. (2002). Tamsulosin: A review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. Drugs & Aging, 19, Emberton, M., Andriole, G. L., de la Rosette, J., Djavan, B., Hoefner, K., Vela Navarrete, R., & Nickel, J. C. (2003). Benign prostatic hyperplasia: A progressive disease of aging men. Urology, 61, Fenter, T. C., Naslund, M. J., Shah, M. B., Eaddy, M. T., & Black, L. (2006). The cost of treating the 10 most prevalent diseases in men 50 years of age or older. American Journal of Managed Care, 12(4 Suppl.), S90-S98. Issa, M. M., Fenter, T. C., Black, L., Grogg, A. L., & Kruep, E. J. (2006). An assessment of the diagnosed prevalence of diseases in men 50 years of age or older. American Journal Managed Care, 12(4 Suppl.), S83-S89. Kirby, R. S., Roehrborn, C., Boyle, P., Bartsch, G., Jardin, A., Cary, M. M., & Grossman, E. B. (2003). Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: The Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology, 61, McConnell, J. D., Barry, M. J., & Bruskewitz, R. C. (1994). Benign prostatic hyperplasia: Diagnosis and treatment. Agency for Health Care Policy and Research. Clinical Practice Guideline. The Quick Reference Guide for Clinicians, 8, McConnell, J. D., Roehrborn, C. G., Bautista, O. M., Andriole, G. L., Jr., Dixon, C. M., Kusek, J. W., & Smith, J. A. (2003). The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. New England Journal of Medicine, 18, Naslund, M., Eaddy, M. T., Hogue, S. L., Kruep, E. J., & Shah, M. B. (2009). Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: Assessment of acute urinary retention and prostaterelated surgery. Current Medical Research and Opinion, 25, Naslund, M., Issa, M., Grogg, A., Eaddy, M., & Black, L. (2006). Clinical and economic outcomes in patients treated for enlarged prostate. American Journal of Managed Care, 12, S111-S116. Rigatti, P., Brausi, M., Scarpa, R. M., Porru, D., Schumacher, H., & Rizzi, C. A. (2003). A comparison of the efficacy and tolerability of tamsulosin and finasteride in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Prostate Cancer and Prostatic Diseases, 6, Roberts, R. O., Jacobsen, S. J., Rhodes, T., Girman, C. J., Guess, H. A., & Lieber, M. M. (1997). Natural history of prostatism: Impaired health states in men with lower urinary tract symptoms. Journal of Urology, 157, Roehrborn, C. G., Boyle, P., Nickel, J. C., Hoefner, K., & Andriole, G. (2002). Efficacy and safety of a dual inhibitor of
6 Kruep et al alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology, 60, Roehrborn, C. G., McConnell, J. D., Barry, M. J., Benaim, E., Bruskewitz, R. C., Blute, M. L., & Stein, B. S. (2003). Guidelines on the management of benign prostatic hyperplasia (BPH). Linthicum, MD: American Urological Association. Roehrborn, C. G., Siami, P., Barkin, J., Damião, R., Becher, E., Miñana, B., & Montorsi, F. (2009). The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study. European Urology, 55, Roehrborn, C. G., Siami, P., Barkin, J., Damião, R., Major- Walker, K., Nandy, I., & Montorsi, F. (2010). The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. European Urology, 57, Rosen, R., Altwein, J., Boyle, P., Kirby, R. S., Lukacs, B., Meuleman, E., & Giuliano, F. (2003). Lower urinary tract symptoms and male sexual dysfunction: The multinational survey of the aging male (MSAM-7). European Urology, 44, Sarma, A. V., Jacobson, D. J., McGree, M. E., Roberts, R. O., Lieber, M. M., & Jacobsen, S. J. (2005). A population-based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmstead County, Minnesota: 1987 to Journal of Urology, 173, Wei, J. T., Calhoun, E., & Jacobsen, S. J. (2005). Urologic diseases in America project: Benign prostatic hyperplasia. Journal of Urology, 173,
REPORTS. Clinical and Economic Outcomes in Patients Treated for Enlarged Prostate
Clinical and Economic Outcomes in Patients Treated for Enlarged Prostate Michael James Naslund, MD, MBA; Muta M. Issa, MD, MBA; Amy L. Grogg, PharmD; Michael T. Eaddy, PharmD, PhD; and Libby Black, PharmD
More informationThe Clinical and Economic Benefit of Early Avodart Use vs Early Finasteride Use (Study: 8AVO027HO)
The Clinical and Economic Benefit of Early Avodart Use vs Early Finasteride Use (Study: 8AVO027HO) November 2011 (Revised May 2012) Prepared for: GlaxoSmithKline Please direct comments and questions to:
More informationGSK Clinical Study Register
In February 2013, GlaxoSmithKline (GSK) announced a commitment to further clinical transparency through the public disclosure of GSK Clinical Study Reports (CSRs) on the GSK Clinical Study Register. The
More informationα-blocker Monotherapy and α-blocker Plus 5-Alpha-Reductase Inhibitor Combination Treatment in Benign Prostatic Hyperplasia; 10 Years Long-Term Results
www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.4.248 Voiding Dysfunction α-blocker Monotherapy and α-blocker Plus 5-Alpha-Reductase Inhibitor Combination Treatment in Benign Prostatic Hyperplasia;
More informationMedical Therapy for Benign Prostatic Hyperplasia Present and Future Impact
REPORTS Medical Therapy for Benign Prostatic Hyperplasia Present and Future Impact Muta M. Issa, MD, MBA; Timothy S. Regan, BPharm, RPh, CPh Abstract The purpose of this manuscript is to provide clinicians,
More informationIncreasing Awareness, Diagnosis, and Treatment of BPH, LUTS, and EP
Introduction to Enlarged Prostate E. David Crawford, MD Professor of Surgery (Urology) and Radiation Oncology Head, Urologic Oncology E. David Crawford Endowed Chair in Urologic Oncology University of
More informationTherapeutic Strategies for Managing BPH Progression
european urology supplements 5 (2006) 997 1003 available at www.sciencedirect.com journal homepage: www.europeanurology.com Therapeutic Strategies for Managing BPH Progression John M. Fitzpatrick a, *,
More informationHow Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia?
available at www.sciencedirect.com journal homepage: www.europeanurology.com How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia?
More informationHyoung Woo Kim, Dae Geun Moon, Hyun Min Kim, Jong Ho Hwang, Soon Chan Kim, Sam Geuk Nam, Jun Tag Park
www.kjurology.org http://dx.doi.org/10.4111/kju.2011.52.10.681 Voiding Dysfunction Effect of Shifting from Combination Therapy to Monotherapy of α-blockers or 5α-Reductase Inhibitors on Prostate Volume
More informationThe Evolution of Combination Therapy. US men eligible for BPH treatment * with projected population changes
The Management of BPH & The Impact of Combination Therapy Results Combination of Avodart and Tamsulosin (CombAT) Medical Therapy of Prostate Symptoms (MTOPS) Dr. Jack Barkin, md, fics, facs, dabu, Mcert
More informationTreatment Patterns in Alpha-Blocker Therapy for Benign Prostatic Hyperplasia
510732JMHXXX10.1177/1557988313510732American Journal of Men s HealthSchoenfeld et al. research-article2013 Article Treatment Patterns in Alpha-Blocker Therapy for Benign Prostatic Hyperplasia American
More informationAlpha-BlockerTherapy Can Be Withdrawn in the Majority of Men Following Initial CombinationTherapy with the Dual 5a-Reductase Inhibitor Dutasteride
European Urology European Urology 44 (2003) 461 466 Alpha-BlockerTherapy Can Be Withdrawn in the Majority of Men Following Initial CombinationTherapy with the Dual 5a-Reductase Inhibitor Dutasteride J.
More informationThe Journal of International Medical Research 2012; 40:
The Journal of International Medical Research 2012; 40: 899 908 Comparison of α-blocker Monotherapy and α-blocker Plus 5α-Reductase Inhibitor Combination Therapy Based on Prostate Volume for Treatment
More informationDrugTreatment of Benign Prostatic Hyperplasia and Hospital Admission for BPH-Related Surgery
European Urology European Urology 43 (2003) 528 534 DrugTreatment of Benign Prostatic Hyperplasia and Hospital Admission for BPH-Related Surgery P.C. Souverein a,*, J.A. Erkens b, J.J.M.C.H. de la Rosette
More informationBenign Prostatic Hyperplasia (BPH):
Benign Prostatic Hyperplasia (BPH): Evidence Based Guidelines for Primary Care Providers Jeanne Martin, DNP, ANP-BC Objectives 1. Understand the pathophysiology and prevalence of BPH 2. Select the appropriate
More informationDuring the past decade, numerous
Benign prostatic hyperplasia (BPH) is one of the most common diseases of aging men. It is estimated that by age 60 years, greater than 50% of men will have histologically documented evidence of the disease.
More informationCombination Drug Therapy for Benign Prostatic Hyperplasia (BPH)
The Annals of African Surgery www.sskenya.org Combination Drug Therapy for Benign Prostatic Hyperplasia (BPH) Author: Oliech J.S. FRCS, Affiliation: Department of Surgery, University of Nairobi. P.O. Box
More informationRecommended drug treatment of BPH in primary care Claire Taylor MRCS, Charlotte Foley MRCS and Roger Kirby MA, MD, FRCS Urol
Drug review BPH Recommended drug treatment of BPH in primary care Claire Taylor MRCS, Charlotte Foley MRCS and Roger Kirby MA, MD, FRCS Urol Skyline Imaging Ltd The development of safe and effective drugs
More informationBenign Prostatic Hyperplasia and Enlarged Prostate Guidelines: How They Can Be Useful to Primary Care
Volume 1, Number 1 Weill Medical College of Cornell University Reports on Men s Urologic Health 1 Editor: Steven A. Kaplan, MD, Professor of Urology, and Chief, Institute for Bladder and Prostate Health,
More informationWill Medical Management of Benign Prostatic Hyperplasia Result in Better or Worse Sexual Function in Men?
Urol Sci 2011;22(1):14 18 MINI REVIEW Will Medical Management of Benign Prostatic Hyperplasia Result in Better or Worse Sexual Function in Men? Thomas I.S. Hwang 1,2,3 * 1 Shin Kong WHS Hospital, Taipei,
More informationThe Hallmarks of BPH Progression and Risk Factors
European Urology Supplements European Urology Supplements 2 (23) 2 7 The Hallmarks of BPH Progression and Risk Factors M. Emberton * Institute of Urology and Nephrology, University College London, 48 Riding
More informationCurrent drug management of BPH in primary care Claire Taylor MRCS, Charlotte Foley MRCS and Roger Kirby MA, MD, FRCS Urol
Drug review BPH Current drug management of BPH in primary care Claire Taylor MRCS, Charlotte Foley MRCS and Roger Kirby MA, MD, FRCS Urol Skyline Imaging Ltd The range of drug treatments for BPH, alone
More informationREVIEW The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia
(2008) 20, S19 S26 & 2008 Nature Publishing Group All rights reserved 0955-9930/08 $30.00 www.nature.com/ijir REVIEW The utility of serum prostatic-specific antigen in the management of men with benign
More informationBenign Prostatic Hypertrophy (BPH) is the most
Medical treatment of benign prostatic hypertrophy There is little doubt that medical therapy has transformed the treatment of benign prostatic hypertrophy (BPH). The medical treatment of BPH continues
More informationBenign Prostatic Hyperplasia. Jay Lee, MD, FRCSC Clinical Associate Professor University of Calgary
Benign Prostatic Hyperplasia Jay Lee, MD, FRCSC Clinical Associate Professor University of Calgary Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied,
More informationThe population of subjects which was statistically analyzed was the Intent-to-Treat population
Study No.: ARIB3003 (Year 1) Title: A Randomized, Double-Blind, Placebo-Controlled, Two-Year Parallel-Group Study of the Efficacy and Safety of GI198745 in the Treatment and Modification of Progression
More informationBenign Prostatic Hyperplasia (BPH) Important Papers / Landmark. Vijayan Manogran
Benign Prostatic Hyperplasia (BPH) Important Papers / Landmark Studies Vijayan Manogran MTOPS & CombAT PLESS SMART ALTESS ALF-ONE VA PREDICT EPICS Landmark Studies MTOPS Medical Therapy of Prostatic Symptoms
More informationA Study of Relationship of Prostate Volume, Prostate Specific Antigen and age in Benign Prostatic Hyperplasia
ORIGINAL RESEARCH www.ijcmr.com A Study of Relationship of Prostate Volume, Prostate Specific Antigen and age in Benign Prostatic Hyperplasia Rupam Deori 1, Bijoyananda Das 2, Mustafa Abdur Rahman 3 ABSTRACT
More informationCan men with prostates sized 80 ml or larger be managed conservatively?
Original Article - Lower Urinary Tract Dysfunction Investig Clin Urol 2017;58:359-364. pissn 2466-0493 eissn 2466-054X Can men with prostates sized 80 ml or larger be managed conservatively? Alvin Lee,
More informationThe Efficacy of Drugs for the Treatment of LUTS/BPH, A Study in 6 European Countries
european urology 51 (2007) 207 216 available at www.sciencedirect.com journal homepage: www.europeanurology.com Benign Prostatic Hyperplasia The Efficacy of Drugs for the Treatment of LUTS/BPH, A Study
More informationManagement of LUTS. Simon Woodhams February 2012
Management of LUTS Simon Woodhams February 2012 The management of lower urinary tract symptoms (LUTS) in men Implementing NICE guidance May 2010 NICE clinical guideline 97 Background Lower urinary tract
More informationOptimising the Medical Management of Benign Prostatic Hyperplasia
European Urology European Urology 45 (2004) 411 419 Review Optimising the Medical Management of Benign Prostatic Hyperplasia Michael Marberger a,*, Richard Harkaway b, Jean de la Rosette c a Department
More informationBPH: a present and future perspective on health impact
BPH: a present and future perspective on health impact Burden of disease in men with moderate LUTS Dalibor Pacík This presentation is financially supported by GlaxoSmithKline. CZ/DUTT/0019/12 Men with
More informationMale LUTS, OAB, Sex: natural history. JR Sathiya
Male LUTS, OAB, Sex: natural history JR Sathiya Definitions Newer concepts of LUTs Natural history of BPH Prevalence of LUTs Definition BPH- represents a histologic diagnosis that refers to the proliferation
More information5-alpha-reductase inhibitors for lower urinary tract symptoms secondary to benign prostatic obstruction(protocol)
Cochrane Database of Systematic Reviews 5-alpha-reductase inhibitors for lower urinary tract symptoms secondary to benign prostatic obstruction(protocol) García-Perdomo HA, Lopez HE, Tacklind J García-Perdomo
More informationThe Relationship Between Prostate Volume, Prostate- Specific Antigen and Age in Saudi Men with Benign Prostatic Conditions
African Journal of Urology 1110-5704 Vol. 16, No. 4, 2010 117-123 Original article The Relationship Between Prostate Volume, Prostate- Specific Antigen and Age in Saudi Men with Benign Prostatic Conditions
More informationThe incidence of acute urinary retention secondary to BPH is increasing among California men
Prostate Cancer and Prostatic Disease (2013) 16, 260 265 & 2013 Macmillan Publishers Limited All rights reserved 1365-7852/13 www.nature.com/pcan ORIGINAL ARTICLE The incidence of acute urinary retention
More informationThe Risk of Fracture with Taking Alpha Blockers for Treating Benign Prostatic Hyperplasia
J Prev Med Public Health 2009;42(3):165-170 DOI: 103961/jpmph2009423165 The Risk of Fracture with Taking Alpha Blockers for Treating Benign Prostatic Hyperplasia Joongyub Lee 1) Nam-Kyoung Choi 13) Sun-Young
More informationMMM. Topic The use of Tadalafil 5mg daily for the treatment of BPH-LUTS
Dr Tan & Partners MMM Vol. 1 No. 1 Morbidity & Mortality Meeting 14 th November 2014 Introduction Topic The use of Tadalafil 5mg daily for the treatment of BPH-LUTS Tadalafil 5mg daily is a well established
More informationIntroduction. Original Article: Clinical Investigation
International Journal of Urology (2015) 22, 582--587 doi: 10.1111/iju.12741 Original Article: Clinical Investigation Treatment satisfaction and clinically meaningful symptom improvement in men with lower
More informationSingle Technology Appraisal (STA) Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia
Comment 1: the draft remit Appendix D - NICE s response to consultee and commentator comments on the draft scope and provisional matrix National Institute for Health and Clinical Excellence Single Technology
More informationGuideline for the primary care management of male lower urinary tract symptoms
review Article GUIDELINES FOR LUTS M.J. SPEAKMAN et al. As my Comment in the first section of the journal suggested, the MTOPS results have offered the possibility to general practitioners of reducing
More informationAlpha antagonists from initial concept to routine clinical practice
european urology 50 (2006) 635 642 available at www.sciencedirect.com journal homepage: www.europeanurology.com Editorial 50th Anniversary Alpha antagonists from initial concept to routine clinical practice
More informationTreating BPH: Comparing Rezum UroLift and HoLEP
Treating BPH: Comparing Rezum UroLift and HoLEP Scott M. Cheney MD Mayo Clinic Arizona 2018 MFMER slide-1 Welcome to AZ 2018 MFMER slide-2 Outline Background on BPH, Rezum, Urolift, HoLEP AUA Guideline
More informationNOTE: This policy is not effective until April 1, Transurethral Water Vapor Thermal Therapy of the Prostate
NOTE: This policy is not effective until April 1, 2019. Medical Policy Manual Surgery, Policy No. 210 Transurethral Water Vapor Thermal Therapy of the Prostate Next Review: December 2019 Last Review: December
More informationEAU GUIDELINES POCKET EDITION 3
EAU GUIDELINES POCKET EDITION 3 CONTENTS: BENIGN PROSTATIC HYPERPLASIA URINARY INCONTINENCE UROLITHIASIS 2 3 EAU POCKET GUIDELINES POCKET EDITION 3 This is one of a series of convenient pocket size books
More informationGENDER HEALTH. Benign Prostatic Hyperplasia. Medical and Surgical Treatment Options
GENDER HEALTH Benign Prostatic Hyperplasia Medical and Surgical Treatment Options ABSTRACT Benign prostatic hyperplasia (BPH) affects the aging male. Treatment options vary widely. Some men will elect
More informationEVALUATION OF THE EFFICACY OF TADALAFIL IN IMPROVING LOWER URINARY TRACT SYMPTOMS IN PATIENTS WITH SYMPTOMATIC BENIGN PROSTATIC ENLARGEMENT
Basrah Journal Of Surgery EVALUATION OF THE EFFICACY OF TADALAFIL IN IMPROVING LOWER URINARY TRACT SYMPTOMS IN PATIENTS WITH SYMPTOMATIC BENIGN PROSTATIC ENLARGEMENT MB, ChB, FIBMS, Assistant Professor
More informationIJBCP International Journal of Basic & Clinical Pharmacology
Print ISSN: 2319-2003 Online ISSN: 2279-0780 IJBCP International Journal of Basic & Clinical Pharmacology DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20172721 Original Research Article Patient-reported
More informationDepartment of Urology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX
NEW PERSPECTIVES ON BPH 5- -Reductase Inhibitors Prevent the Progression of Benign Prostatic Hyperplasia Claus G. Roehrborn, MD Department of Urology, The University of Texas Southwestern Medical Center
More informationKey words: Lower Urinary Tract Symptoms (LUTS), Prostatic Hyperplasia, Alpha-1 Adrenoceptor Antagonists, Tamsulosin, Terazosin.
The Professional Medical Journal DOI: 10.17957/TPMJ/17.4102 ORIGINAL PROF-4102 PROSTATIC HYPERPLASIA; COMPARISON BETWEEN TAMSULOSIN AND TERAZOSIN FOR EFFICACY IN MEDICAL MANAGEMENT OF LOWER URINARY TRACT
More informationREVIEW The role of combination medical therapy in benign prostatic hyperplasia
(2008) 20, S33 S43 & 2008 Nature Publishing Group All rights reserved 0955-9930/08 $30.00 www.nature.com/ijir REVIEW The role of combination medical therapy in benign prostatic hyperplasia Department of
More informationJMSCR Vol 05 Issue 07 Page July 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i7.47 Original Research Article Tadalafil therapy
More informationCombination of α-blocker and 5αreductase inhibitor for treatment of benign prostatic hyperplasia
ORIGINAL RESEARCH Deying Kang, MD 1 Caoyang Hu, MS 2 Yanyan Fu, MD, PhD 3 Dongwen Wang, MD, PhD 4,* 1Department of Evidence based Medicine and Clinical Epidemiology, West China Hospital, Sichuan University,
More informationDOWNLOAD OR READ : TREATMENT OF BENIGN PROSTATIC HYPERPLASIA PDF EBOOK EPUB MOBI
DOWNLOAD OR READ : TREATMENT OF BENIGN PROSTATIC HYPERPLASIA PDF EBOOK EPUB MOBI Page 1 Page 2 treatment of benign prostatic hyperplasia treatment of benign prostatic pdf treatment of benign prostatic
More informationEuropean Healthcare Innovation Leadership Network
MAY 2008 The Value Proposition of Medicines to Treat Benign Prostatic Hyperplasia: Introduction The following case study examines the evolution of Avodart, a drug manufactured by GSK that is currently
More informationComments concerning the real risk of sexual adverse events secondary to the use of 5-ARIs
ORIGINAL PAPER DOI: 10.4081/aiua.2015.4.312 Comments concerning the real risk of sexual adverse events secondary to the use of 5-ARIs Furio Pirozzi Farina, Antonella Pischedda Andrological Urology Unit,
More informationClass Update: Benign Prostatic Hyperplasia (BPH)
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationTherapeutic Class Overview Benign Prostatic Hyperplasia (BPH) Treatments
Therapeutic Class Overview Benign Prostatic Hyperplasia (BPH) Treatments Therapeutic Class Overview/Summary: The agents approved for the treatment of signs and symptoms of benign prostatic hyperplasia
More informationImpact of 5-Alpha Reductase Inhibitors Treatment for Benign Prostatic Hyperplasia on Erectile Dysfunction: A Meta-Analysis
International Journal of Clinical Urology 2017; 1(1): 1-6 http://www.sciencepublishinggroup.com/j/ijcu doi: 10.11648/j. ijcu.20170101.11 Review Article Impact of 5-Alpha Reductase Inhibitors Treatment
More informationMedical management of Benign Prostate Hyperplasia: New insights
INTERNATIONAL JOURNAL OF CURRENT RESEARCH IN BIOLOGY AND MEDICINE ISSN: 2455-944X www.darshanpublishers.com DOI:10.22192/ijcrbm Volume 2, Issue 5-2017 Original Research Article Medical management of Benign
More informationLow Incidence of Acute Urinary Retention in the General Male Population: TheTriumph Project
European Urology European Urology 47 (2005) 494 498 Low Incidence of Acute Urinary Retention in the General Male Population: TheTriumph Project K.M.C. Verhamme a,b, *, J.P. Dieleman a, M.A.M. van Wijk
More informationMedical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily
REVIEW Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily Claus G Roehrborn 1 Raymond C Rosen 2 1 Department of Urology, University of Texas Southwestern
More informationElements for a Public Summary
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Benign prostatic hyperplasia (BPH), also called benign prostatic hypertrophy or benign prostatic obstruction, is a condition in
More informationPATIENT INFORMATION 2017 NeoTract, Inc. All rights reserved. Printed in the USA. MAC Rev A
PATIENT INFORMATION OVER 70% OF MEN IN THEIR 60s HAVE SYMPTOMS OF BPH 1 BPH affects more than 500 million men worldwide, with many men suffering from symptoms of enlarged prostate. 1 You no longer have
More informationLiterature Scan: Drugs for BPH
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationMEDICAL THERAPY. Endocrine Approaches. Página 1 de 5.
Página 1 de 5 MEDICAL THERAPY Part of "32 - BENIGN PROSTATIC HYPERPLASIA" Use of pharmacologically defined and a variety of so-called alternative medications to attempt to improve BPH voiding dysfunction
More informationEvaluation of Sexual Dysfunction in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Patients
Original Article Print ISSN: 2321-6379 Online ISSN: 2321-595X DOI: 10.17354/ijss/2018/10 Evaluation of Sexual Dysfunction in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Patients N. Narayanamoorthy,
More informationDepartment of Urology, Hirosaki University Graduate School of Medicine, Hirosaki , Japan
BioMed Research International Volume 216, Article ID 4975851, 5 pages http://dx.doi.org/1.1155/216/4975851 Clinical Study Efficacy and Safety of Silodosin and Dutasteride Combination Therapy in Acute Urinary
More informationOriginal Article - Sexual Dysfunction
www.kjurology.org http://dx.doi.org/10.4111/kju.2014.55.9.608 Original Article - Sexual Dysfunction http://crossmark.crossref.org/dialog/?doi=10.4111/kju.2014.55.9.608&domain=pdf&date_stamp=2014-09-16
More informationCONDUCT study A step further in changing treatment paradigm in BPH
CONDUCT study A step further in changing treatment paradigm in BPH CLUJ,25.09.2015, Adriana Stoica, Medical Advisor GSK Toate informa,ile con,nute in aceasta prezentare sunt conforme cu Rezumatul caracteris,cilor
More informationOffice Management of Benign Prostatic Enlargement
Focus on CME at McGill University Office Management of Benign Prostatic Enlargement Symptomatic benign prostate enlargement is a common medical problem encountered in our aging society. Watchful waiting,
More informationIJBCP International Journal of Basic & Clinical Pharmacology
Print ISSN: 2319-2003 Online ISSN: 2279-0780 IJBCP International Journal of Basic & Clinical Pharmacology DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20160772 Research Article Efficacy and safety of
More informationChapter 4: Research and Future Directions
Chapter 4: Research and Future Directions Introduction Many of the future research needs listed in the 1994 Agency for Health Care Policy and Research (AHCPR) clinical practice guideline Benign Prostatic
More informationTitle of Research Thesis:
Eastern Michigan University By Fatai Osinowo Adviser s Name: Dr. Stephen Sonstein, PhD Title of Research Thesis: A sub-analyses from the Benign Prostatic Hyperplasia (BPH) Registry and Patient survey:
More informationChapter 3: Results of the Treatment Outcomes Analyses
Chapter 3: Results of the Treatment Outcomes Analyses TABLE OF CONTENTS INTRODUCTION... 3 WATCHFUL WAITING... 11 STUDY OUTCOMES... 11 MEDICAL THERAPIES... 13 ALPHA-ADRENERGIC ANTAGONISTS (ALPHA-BLOCKERS)...
More informationTransurethral resection of the prostate (TURP)
This information tells you about an operation on the prostate called a transurethral resection of the prostate (TURP). It explains how the operation is done, how it can help, what the risks are and what
More informationPRABHAKAR SINGH*, MANOJ INDURKAR, AMITA SINGH, PALLAVI INDURKAR
Academic Sciences International Journal of Current Pharmaceutical Research ISSN- 0975-7066 Vol 5, Issue 1, 2013 Research Article COMPARISON OF THE EFFICACY AND SAFETY OF TAMSULOSIN (0.4 V/S (and) FINASTERIDE
More informationOriginal Policy Date
MP 7.01.39 Transurethral Microwave Thermotherapy Medical Policy Section Surgery Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return to Medical
More informationLONG-TERM SAFETY AND EFFICACY OF TAMSULOSIN FOR THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA
0022-5347/03/1702-0498/0 Vol. 170, 498 502, August 2003 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2003 by AMERICAN UROLOGICAL ASSOCIATION DOI: 10.1097/01.ju.0000076140.68657.fd LONG-TERM SAFETY
More informationMonth/Year of Review: May 2014 Date of Last Review: November 2012 Source Document: OSU College of Pharmacy
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2012 Oregon State University. All Rights
More informationj 727
Efficacy and Safety of the Coadministration of Tadalafil Once Daily with Finasteride for 6 Months in Men with Lower Urinary Tract Symptoms and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia
More information50% of men. 90% of men PATIENT FACTSHEET: BPH CONDITION AND TREATMENTS. Want more information? What are the symptoms?
PATIENT FACTSHEET: BPH CONDITION AND TREATMENTS What is Benign Prostatic Hyperplasia (enlarged prostate)? Benign prostatic hyperplasia (BPH) is a noncancerous enlargement of the prostate, the gland that
More informationProstate Gland Volume and Its Relationship to Complications of Benign Prostatic Enlargement
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 14, Issue 6 Ver. II (Jun. 2015), PP 33-37 www.iosrjournals.org Prostate Gland Volume and Its Relationship
More informationProstate Disease. Chad Baxter, MD
Prostate Disease Chad Baxter, MD Managing BPH and LUTS Chad Baxter, MD Department of Urology cbaxter@mednet.ucla.edu 33 nd Annual UCLA Intensive Course in Geriatric Medicine & Board Review Prevalence of
More informationIndex. urologic.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Ablative therapies, transurethral needle ablation, Adverse events, sexual side effects of BPH Aging, and incidence of BPH associated with
More informationFEP Medical Policy Manual
FEP Medical Policy Manual Effective Date: April 15, 2018 Related Policies: None Prostatic Urethral Lift Description Benign prostatic hyperplasia (BPH) is a common condition in older individuals that can
More informationOverview. Urology Dine and Learn: Erectile Dysfunction & Benign Prostatic Hyperplasia. Iain McAuley September 15, 2014
Urology Dine and Learn: Erectile Dysfunction & Benign Prostatic Hyperplasia Iain McAuley September 15, 2014 Overview Review of the most recent guidelines for ED and BPH ED Guidelines CUA 2006 AUA 2011
More informationMedical Coverage Policy Prostatic Urethral Lifts
Medical Coverage Policy Prostatic Urethral Lifts EFFECTIVE DATE:12 01 2018 POLICY LAST UPDATED: 10 03 2017 OVERVIEW Benign prostatic hyperplasia is a common condition in older men that can lead to increased
More informationBPH: Social Impact and Patient s Perspective
european urology supplements 5 (2006) 991 996 available at www.sciencedirect.com journal homepage: www.europeanurology.com BPH: Social Impact and Patient s Perspective Mark Emberton a, *, Guiseppe Martorana
More informationThe potential for NX-1207 in benign prostatic hyperplasia: an update for clinicians
Therapeutic Advances in Chronic Disease Review The potential for NX-1207 in benign prostatic hyperplasia: an update for clinicians Neal Shore and Barrett Cowan Ther Adv Chronic Dis (2011) 2(6) 377 383
More informationSacit Nuri Gorgel, Ertugrul Sefik, Osman Kose, Vural Olgunelma, Evren Sahin
ORIGINAL Article Vol. 39 (5): 657-662, September - October, 2013 doi: 10.1590/S1677-5538.IBJU.2013.05.07 The Effect of Combined Therapy with Tamsulosin Hydrochloride and Meloxicam in Patients with Benign
More informationCurrent role of treatment in men with lower urinary tract symptoms combined with overactive bladder
Review Article Prostate Int 2014;2(2):43-49 P ROSTATE INTERNATIONAL Current role of treatment in men with lower urinary tract symptoms combined with overactive bladder Seung Hwan Lee, Ji Youl Lee 1 Department
More informationThe Relationship between Prostate Inflammation and Lower Urinary Tract Symptoms: Examination of Baseline Data from the REDUCE Trial
european urology 54 (2008) 1379 1384 available at www.sciencedirect.com journal homepage: www.europeanurology.com Benign Prostatic Hyperplasia The Relationship between Prostate Inflammation and Lower Urinary
More informationEvidence-based guidelines in lower urinary tract symptoms secondary to benign prostatic hyperplasia and variation in care
REVIEW C URRENT OPINION Evidence-based guidelines in lower urinary tract symptoms secondary to benign prostatic hyperplasia and variation in care Seth A. Strope Purpose of review Guidelines have been developed
More informationChapter 3: Results of the Treatment Outcomes Analyses
Chapter 3: Results of the Treatment Outcomes Analyses Introduction To determine the appropriateness of individual therapies, as well as to develop practice recommendations, the American Urological Association
More informationTABLE 1. Differential Diagnosis of Symptomatic BPH* Category Cause of BPH Comments Malignant Adenocarcinoma of the prostate, transitional Men should b
CONCISE BENIGN PROSTATIC REVIEW HYPERPLASIA FOR CLINICIANS Evaluation and Medical Management of Benign Prostatic Hyperplasia THOMAS J. BECKMAN, MD, AND LANCE A. MYNDERSE, MD Benign prostatic hyperplasia
More informationFEP Medical Policy Manual
FEP Medical Policy Manual Effective Date: January 15, 2019 Related Policies: None Prostatic Urethral Lift Description Benign prostatic hyperplasia (BPH) is a common condition in older individuals that
More information